These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37545423)

  • 1. Things We Do for No Reason™: Deferring bisphosphonate initiation to the outpatient setting after fragility hip fracture.
    Freeman S; Mujahid N
    J Hosp Med; 2024 May; 19(5):417-420. PubMed ID: 37545423
    [No Abstract]   [Full Text] [Related]  

  • 2. Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial.
    Adachi JD; Lyles K; Boonen S; Colón-Emeric C; Hyldstrup L; Nordsletten L; Pieper C; Recknor C; Su G; Bucci-Rechtweg C; Magaziner J
    Calcif Tissue Int; 2011 Dec; 89(6):427-33. PubMed ID: 22038744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
    Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
    Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?
    Yoon RS; Hwang JS; Beebe KS
    J Bone Joint Surg Br; 2011 Oct; 93(10):1289-95. PubMed ID: 21969423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate Use After Hip Fracture in Older Adults: A Nationwide Retrospective Cohort Study.
    Nordström P; Toots A; Gustafson Y; Thorngren KG; Hommel A; Nordström A
    J Am Med Dir Assoc; 2017 Jun; 18(6):515-521. PubMed ID: 28238673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort.
    Won SH; Ahn S; Ji E; Park JW; Kim JK; Lee YK
    J Korean Med Sci; 2020 Jun; 35(25):e193. PubMed ID: 32597040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and mortality: confounding in observational studies?
    Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
    Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
    N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
    Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P
    Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on Lee et al.: incidence of second hip fracture and compliant use of bisphosphonate.
    Zhu Y; Chen W; Zhang Y
    Osteoporos Int; 2014 Sep; 25(9):2325. PubMed ID: 24819453
    [No Abstract]   [Full Text] [Related]  

  • 13. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
    Soen S
    Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.
    Safford MM; Barasch A; Curtis JR; Outman R; Saag K
    J Clin Rheumatol; 2014 Oct; 20(7):357-62. PubMed ID: 25275761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of second hip fracture and compliant use of bisphosphonate.
    Lee YK; Ha YC; Yoon BH; Koo KH
    Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis and its complications.
    Varacallo MA; Fox EJ
    Med Clin North Am; 2014 Jul; 98(4):817-31, xii-xiii. PubMed ID: 24994054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fracture Risk During and After Bisphosphonate Drug Holidays: A Matter of Methods?
    Adams AL
    Med Care; 2020 May; 58(5):417-418. PubMed ID: 32149922
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-yearly zoledronic acid in hip fracture prevention.
    Demontiero O; Duque G
    Clin Interv Aging; 2009; 4():153-64. PubMed ID: 19503777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.